Review Article

MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge

David Roulois,1,2,3 Marc Grégoire,1,2,3 and Jean-François Fonteneau1,2,3

1 UMR892, INSERM, Institut de Recherche Thérapeutique, Université de Nantes, 8 quai Moncousu, BP70721, 44007 Nantes Cedex 1, France
2 CNRS, UMR6299, Institut de Recherche Thérapeutique, Université de Nantes, 8 quai Moncousu, BP70721, 44007 Nantes Cedex 1, France
3 Faculté de Médecine, Université de Nantes, 44035 Nantes Cedex 1, France

Correspondence should be addressed to Jean-François Fonteneau; jean-francois.fonteneau@inserm.fr

Received 18 May 2012; Accepted 6 July 2012

Academic Editor: Julie Curtsinger

Copyright © 2013 David Roulois et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

MUC1 glycoprotein is often found overexpressed and hypoglycosylated in tumor cells from numerous cancer types. Since its discovery MUC1 has been an attractive target for antitumor immunotherapy. Indeed, in vitro and in vivo experiments have shown T-cell-specific responses against MUC1 in an HLA-restricted and HLA-unrestricted manner, although some animal models have highlighted the possible development of tolerogenic responses against this antigen. These observations permit the development of new T-cell vaccine strategies capable of inducing an MUC1-specific cytotoxic T cell response in cancer patients. Some of these strategies are now being tested in clinical trials against different types of cancer. To date, encouraging clinical responses have been observed with some MUC1 vaccines in phase II/III clinical trials. This paper compiles knowledge regarding MUC1 as a promising tumor antigen for antitumor therapeutic vaccines applicable to numerous cancers. We also summarize the results of MUC1-vaccine-based clinical trials.

1. Introduction

With the increasing number of cancers, the development of innovative cancer therapies is a great challenge. One of these innovative strategies is immunotherapy. Since the discovery that the immune system can control cancer progression, which has been conceptualized in the “three Es” theory [1] for “elimination, equilibrium, and escape,” supporting the implications of the immune system in the control and selection of tumor cells, scientists and clinicians have tried to exploit this phenomenon to induce an antitumor immune response in cancer patients. Major goals in the field of immunotherapy are to understand how the immune system can be specifically activated against cancer cells and to identify relevant antigenic cancer targets.

The first human tumor-associated antigen (TAA) to be discovered, recognized by cytotoxic CD8+ T lymphocytes (CTL), was MAGE-A1 which was identified from tumor-infiltrating lymphocytes obtained after culture of a melanoma biopsy [2]. Since then, many other TAAs have been identified (for review see [3]). Certain TAAs are restricted to one or a few cancer types, such as the “mutated TAA” (BCR-ABL fusion, B-raf, k-ras, N-ras, p53, etc.), or the “differentiation TAA” (Melan-A/MART1, gp100, CEA, PSA, etc.), whereas others are shared between a wide range of cancers, such as the “shared tumor-specific TAA” (MAGE, NYESO-1, SSX, etc.) or the “overexpressed TAA” (HER-2/Neu, p53, Telomerase, MUC1, etc.) (http://www.archive.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm).

Mucin 1 (MUC1) belongs to the “overexpressed TAA” category, even if this overexpression is not the only hallmark of MUC1 in tumor cells, since it is often accompanied by modification of MUC1 glycosylation status. In healthy cells, MUC1 is a glycoprotein expressed at the apical surface of epithelial cells and characterized by a high glycosylation level. In cancers, this glycoprotein is often overexpressed by tumor cells, with a loss of polarity and, interestingly, a modification of its glycosylation pattern [4]. Both the
overexpression and the modification of its glycosylation status make this protein highly immunogenic and, thus, an interesting target in cancer immunotherapy. In this paper, we focus on the immunogenic properties of the MUC1 glycoprotein. However, it should be noted that MUC1 has also been described as having an oncogenic role (for review see: [5, 6]). Firstly, we describe the differences between MUC1 expression in healthy cells and tumor cells which renders MUC1 more immunogenic when it is expressed by tumor cells. Secondly, we discuss the problem of induction of tolerance against MUC1 which can impair the antitumor immune response. We list the immunotherapy strategies for inducing an antitumor response in patients, which are being developed in vitro and in mouse models. Finally, we discuss MUC1-based immunotherapy clinical trials against cancers.

2. MUC1: An Overexpressed, Hypoglycosylated, Tumor-Associated Antigen

The MUC1 gene was cloned in the early 1990s [7, 8]. It belongs to the mucin family, comprising 21 members. MUC1 encodes a highly glycosylated, type I transmembrane glycoprotein, with a variable number of 20-amino-acid repeat sequences referred to as “variable number tandem repeat” (VNTR) (Figure 1). The number of VNTR is variable from one allele to another, varying from 25 to 120 VNTR per MUC1 molecule, with the alleles containing 40 and 66 VNTR being the most frequent in the northern European population [7]. Each VNTR contains five potential sites of O-glycosylation on serine or threonine.

Towards the end of the 1980s, differences between the MUC1 expressed by healthy mammary cells and by breast cancer cells were observed using the monoclonal antibody, SM-3, specific for the MUC1 core protein stripped of sugars [9, 10]. Indeed, SM-3 mAb used in histology recognized 91% of breast cancer samples, but showed little or no reactivity with healthy mammary cells [9]. The SM-3 mAb was also reactive against lung, colon, and ovarian carcinoma, but failed to stain the healthy cell counterparts [10]. These studies showed that, in different types of carcinoma, MUC1 is hypoglycosylated. This hypoglycosylation allows recognition by the SM-3 mAb. Since then, MUC1 was considered to be a “tumor-associated antigen” which can be targeted in immunotherapy using monoclonal antibodies. It has subsequently been shown that the glycosylation structures of MUC1 expressed by normal breast cells and tumor cells are different. Indeed, in healthy cells MUC1 contains extended, core 2-based glycans that are formed by N-acetylglucosamine attachment to the GalNAc of core 1, while on the MUC1 expressed by tumor cells the glycans are shorter, core 1-based and richer in ST, Tn, and T glycans [11–13].

These differences observed between MUC1 expressed by tumor cells and healthy cells prompted research on the capacity of T lymphocytes to recognize tumoral MUC1 epitopes. T lymphocytes usually recognize, with their T-cell receptors, peptides from endogenous or exogenous antigens presented in association with MHC molecules. Surprisingly, the first report of recognition of MUC1 by T lymphocytes was shown to be non-MHC-restricted [14]. Indeed the T lymphocytes obtained from a pancreatic cancer patient did not recognize an MUC1 peptide presented by an MHC molecule, but rather, directly, the hypoglycosylated core of MUC1. This unusual antigen recognition was confirmed by other groups [15–18]. The reactivity of these T cells was inhibited by SM-3 mAb, which showed that these T cells recognize the hypoglycosylated core of MUC1. Furthermore, these T cells failed to recognize healthy epithelial cells, which were not stained by the SM-3 mAb. Finally, Hinoda and colleagues described an increased recognition of gastric tumor cells cultured with benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside (BGN), a competitive inhibitor of O-glycosylation, by an HLA-unrestricted, MUC1-specific CTL line [19]. All of these results suggest that a non-MHC-restricted, hypoglycosylated, MUC1-specific T-cell response can be present spontaneously in cancer patients.

In the mid 1990s, efforts were made to identify HLA-restricted, MUC1-specific T-cell responses. Indeed, progress made in the understanding of the T-lymphocyte response against tumor cells allowed the development of new strategies to identify TAA, such as “reverse immunology”. This consists of inducing in vitro T-lymphocyte responses against peptides from a candidate TAA. Peptides are selected for their capacity to bind a particular HLA allele. The capacity of peptide-responding T cells to recognize a tumor cell line which expresses the candidate TAA and the particular HLA allele is then tested to validate the epitope. Using this approach, Domenech’s team, and a new peptide, APDTRPA [21]. These peptides were able to induce CD8+ cytotoxic T-cell responses in HLA-A∗0201 transgenic mice, Apostolopoulos and colleagues identified two peptides from the VNTR able to bind HLA-A∗0201 molecule, which are the most common HLA class I allele in the Caucasian population: the peptide, STAPPAHGV, previously described by Domenech’s team, and a new peptide, APDTRPA [21]. These peptides were able to induce CD8+ cytotoxic T-cell responses in HLA-A∗0201/Kb transgenic mice. The T cells were able to lyse the HLA-A∗0201+ MUC1+ breast cancer cell line, MCF-7. Brossart and colleagues then selected two other peptides from MUC1: MUC1(20–28) LLLLTVLTV and MUC1(950–958) STAPPVHNV, which exhibit a good affinity for the HLA-A∗0201 molecule [22]. The STAPPVHNV peptide is not encoded by the VNTR, but by the region flanking it, whereas the LLLLTVLTV peptide is encoded by the signal sequence of MUC1. Brossart and colleagues generated two CD8+ T-cell clones specific for the HLA-A∗0201/MUC1(20–28) and HLA-A∗0201/MUC1(950–958) complexes. These clones were able to recognize MUC1+ HLA-A∗0201+ tumor cell lines from different types of
Variable number tandem repeats (20 to 120 VNTR per MUC1 molecule)

Unglycosylated MUC-1

Hyperglycosylated MUC-1

Hypoglycosylated MUC-1

Unglycosylated MUC1 (potential glycosylation site on serine or threonine in red)

Core-1 glycosylations: low level and aberrant glycosylations (Tn antigen)

Core-2 glycosylations

Figure 1: Structure of the MUC1 glycoprotein in normal and tumor cells.

cancer: breast, pancreatic, and renal. In another study, the same researchers showed that these MUC1-specific T-cell clones were also able to recognize multiple myeloma cells and primary acute myelogenous leukemia blasts [23]. More recently, we showed that MUC1(950–958) peptide is presented to MUC1-specific CD8+ T cells by HLA-A*0201+ malignant pleural mesothelioma cell lines [24]. In addition, Ninkovic and colleagues reported that some glycosylated peptides from the VNTR of MUC1, notably the decamer SAP10 [SAPDT(GalNAc)RPAPG], can be generated by the immunoproteasome of dendritic cells [25]. This glycosylated peptide can be presented by HLA class I molecules and recognized by CD8+ T cells. The nonglycosylated peptide was also recognized by CD8+ T cells, whereas a peptide with a longer sugar chain (Gal-GalNac) did not bind the HLA-A*0201 molecule. Finally, MUC1 can also be recognized by CD4+ T lymphocytes. However, in this case, only one HLA-DR3-restricted epitope encoded by the VNTR has been identified by "reverse immunology" [26]. Unfortunately, the capacity for presentation by tumor cells was not tested since they do not express HLA class II molecules.

Regarding the recognition of MUC1 peptides by HLA-restricted T lymphocytes, the importance of the MUC1 glycosylation status is not as clear as in the case of HLA-unrestricted recognition of MUC1. We showed recently that the MUC1 glycosylation level does not affect the recognition of mesothelioma tumor cells by an HLA-A*0201/MUC1(950–958)-specific CD8+ T-cell clone [24]. Indeed, we observed that some tumor cell lines recognized by the CD8+ T-cell clone were weakly stained with the SM-3 antibody and another mAb specific for hypoglycosylated MUC1, VU-3-C6. Furthermore, MPM cell lines treated with benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside (BGN), a competitive inhibitor of O-glycosylation, were not better recognized by the T-cell clone, despite an increased staining with the SM-3 and VU-3-C6 mAb. However, other HLA-restricted MUC1 epitopes seem to be dependent on the hypoglycosylation status of MUC1, at least for the induction of the MUC1-specific T-cell response by antigen-presenting cells such as dendritic cells (DC). Indeed, Hiltbold and colleagues reported that glycosylation of long peptides, consisting of five MUC1 tandem-repeat regions, decreased the processing and the HLA-A1 restricted cross-presentation to CD8+ T cells by DC of a nine-amino-acid peptide contained in this long peptide [27]. Furthermore, the modification of MUC1 glycosylation in cancer cells may increase the capacity of DC to acquire this antigen for cross-presentation. Indeed, in cancer, soluble MUC1 presents an aberrant pattern of glycosylation, notably the Tn antigen, which can be recognized and internalized by the C-type lectin receptor macrophage galactose-type lectin (CLR MGL) present on DC and macrophages [28, 29]. This internalization of the soluble form of this tumoral form of MUC1 antigen by DC has also been shown to be mediated by the mannose receptor [30]. However, the retention of internalized MUC1 in the early endosome by this receptor inhibits its presentation to CD4+ T cells, whereas the nonglycosylated form of the antigen is well presented. Conversely, Vlad and colleagues reported that DC exposed to a long-glycosylated MUC1 peptide were able to process and present a glycosylated shorter peptide, in association with class II HLA, to CD4+ T cells suggesting that glycosylated MUC1 peptide can be processed by dendritic cells [28]. In addition, it has been shown that the glycosylation status
influences, but does not inhibit, the cleavage of MUC1 by the immunoproteasome expressed by mature DC [31]. All of these studies underline the capacity of dendritic cells (DC) to distinguish normal from aberrant MUC1. This shows the importance of MUC1 glycosylation, which affects differently the presentation of abnormal MUC1 in MHC class I and II molecules according to the MUC1 epitope studied.

3. Human MUC1 Mouse Model and Tolerance

With the goal of studying the immunogenicity of MUC1 in vivo and of developing MUC1-based cancer immunotherapy, human MUC1 transgenic mouse (TG mice) tumor models were set up by the group of Papadimitriou [32]. These authors reported that the expression of human MUC1 in TG mice was closely similar to that observed in human tissue. Since then, different teams have used these TG mice to study tolerance against MUC1 and how to induce in vivo an MUC1 tumor-specific T-cell response [33–35]. Rowse and colleagues compared tumor growth of MUC1+ tumors in TG or Wt mice [35]. They also compared the induction of an MUC1-specific humoral response after immunization with MUC1 peptide. MUC1+ tumors grew in TG mice, whereas they were rejected in Wt mice, suggesting that a tolerance to MUC1 is present in TG mice. MUC1 immunization of Wt mice was rejected in Wt mice, suggesting that a tolerance to MUC1 occurs in Wt mice [37]. When CD4+ T cells were transferred from B16-bearing WT mice to B16-bearing TG mice, an increase in survival was observed. Furthermore, WT mice challenged with MUC1-expressing B16 tumors mounted an IgG response against MUC1, whereas this IgG response was absent in TG mice [36]. Human MUC1 TG mice have since been crossed with conditional-endometriosis transgenic mice, showing the presence of regulatory Foxp3+ T cells and antibodies against MUC1 during endometriosis, with potential implications for cancer progression [38]. All of these studies, thus, show that a certain degree of MUC1 tolerance is established in vivo. MUC1-based immunotherapy strategies should take into account this phenomenon.

Indeed, these in vivo studies highlight the potential problem of MUC1 tolerance in humans. MUC1 is naturally expressed, and tolerogenic responses can occur in patients leading to tumor escape against the immune system. The MUC1 TG mouse tumor model seems to back up the idea of tolerance against MUC1 in humans, but the modifications of MUC1 glycosylation observed in human cancer cells were not taken into account in these studies. In vivo investigations using vaccination against MUC1 with glycosylated or nonglycosylated peptide suggest that tolerance is not established against epitopes of MUC1 carrying a tumor-specific pattern of glycosylation, such as the Tn antigen [39–41]. Thus, abnormal glycosylation patterns can be recognized as foreign rather than self-antigen, which seems to be important in the induction of a specific T-cell response [39, 40]. MUC1 can, thus, be considered as an “abnormal self-antigen” when its glycosylation status is modified in tumor cells and this is an interesting property that could be exploited in immunotherapy [42].

4. Strategy to Induce MUC1-Specific T-Cell Responses

Different approaches have been developed to induce MUC1-specific T-cell responses in cancer patients. The majority of these are based on the capacity of DC to activate specific T-cell immune responses [53]. We have summarized these approaches in Table 1 and focus on the two most-studied strategies: MUC1-encoding nucleic acids or peptidic vaccination.

One approach consists of the utilization of MUC1 DNA as a vaccine [50, 52, 54]. This strategy has the advantage of activating different populations of lymphocytes, contrary to the use of MHC class I or class II peptides. In these studies, injections of MUC1 cDNA vaccine to tumor-bearing mice were able to induce tumor regressions. However, in two studies, the effector T cells were identified as CD8+ cytotoxic T cells [52, 54], whereas in the last one, the antitumor response was attributed to CD4+ T cells [50]. Studies are now being performed to improve this approach, notably by adding to the MUC1 cDNA a maturation signal for DC. Indeed, one approach consists of coupling MUC1 DNA with DNA corresponding to the expression of a heat shock protein (HSP70) which has already been reported to improve the stimulatory properties of DC [55]. In this study, MUC1/HSP70-coupled DNA increased the capacity of DC to induce effective cytotoxic T-cell responses and inhibited tumor cell growth [45]. Another strategy which has been developed to improve MUC1 cDNA vaccination consists of combining the vaccine with a tumor-cell-death inducer, such as a cDNA interfering with the expression of ANT2, a protein implicated in carcinogenesis [51]. CD8+ T-cell responses were more effective using this combination than with the use of MUC1 cDNA alone. To target MUC1 cDNA expression only to DC, in vitro transfection of human DC with MUC1 mRNA has also been developed [46]. These MUC1-mRNA-transfected DC were able to induce MUC1-specific CD8+ T lymphocytes that can kill pancreatic cancer cells. Finally, to improve the MUC1 cDNA strategies, another interesting study suggested the use of a modified MUC1 sequence, in order to prevent normal glycosylation of the MUC1 protein in dendritic and cancer cells [47].

Another vaccination strategy which has been studied preclinically, in mice, consists of the use of MUC1 peptide or glycopeptides. For this strategy, the use of glycopeptides with tumor-specific sugar motifs, such as the Tn antigen, seems to be more efficient than the use of normal peptides in eliciting an effective immune response [39, 40]. The MUC1 peptide can also be modified to increase its penetration into antigen-presenting cells, for example, the MUC1-MPA(11)P peptide which improved the induction of tumor regression in
Table 1: Strategies for the induction of anti-MUC1 T cell responses that are being studied in vitro and in vivo.

| Author          | Strategy                                      | Cancer Model                  | Effect                                                  |
|-----------------|-----------------------------------------------|-------------------------------|---------------------------------------------------------|
| Deguchi et al.  | α-gal epitope to increase immunogenicity of MUC1 | Pancreatic cancer mouse model | Antibody induction, mouse tumor regression, induction of T cell responses |
| Kovjazin et al. | ImMucin peptide 21mer                         | Mouse/PMHC of patients         | CD4+ and CD8+ T lymphocyte responses in vitro and in vivo |
| Choi et al.     | DNA vaccine (MUC1/HSP70)                       | B16 mice                      | Cytotoxic T cell response induction/ tumor growth inhibition |
| Chen et al.     | MUC1 mRNA, dendritic cell transfection        | Pancreatic cancer              | MUC1 mRNA-transfected dendritic cells can induce MUC1-specific CD8+ T cell responses |
| Wright et al.   | MUC1 peptide with substitution of O-glycosylation site | Human adenocarcinoma          | O-glycosylation site substitution improves immunogenicity |
| Kobukai et al.  | MPA11P vehicle of a 30mer MUC1 peptide        | Mouse                         | Reduction of tumor size, lymphocyte infiltration |
| Lakshmiarayanan et al. | Tripartite MUC1 vaccine (TLR2, Thelpher, MUC1 glycopeptides) | Mouse model of mammary cancer | IgG antibodies, cytotoxic T lymphocytes, activation of innate immune response |
| Sugira et al.   | MUC1 DNA vaccine                              | Mouse/colon                    | Induction of CD4+ T cell responses, not CD8+ T cell responses against glycosylated peptides, but not unglycosylated peptides |
| Ryan et al.     | TN MUC1 glycopeptide                          | Mouse                         | Combination enhanced effects of DNA vaccination, MUC1 CD8+ T cell responses |
| Choi et al.     | MUC1 DNA vaccination, enhanced by mANT2 shRNA  | Mouse melanoma                | Tumor growth inhibition, CD8+ IFN-γ increased |

an animal model [48]. Targeting of MUC1 peptide to antigen-presenting cells can also be improved by adding oxidized (T-cell response, weak antibody level) or reduced mannan (T-cell response, high antibody level) [41]. Another interesting approach was recently developed using a plant model which can produce MUC1 glycopeptides that are able to break tolerance in MUC1 Tg mice vaccinated with this peptide by the production of MUC1-specific antibodies [56]. Some long MUC1 peptides containing MHC class I and class II epitopes (21 mer) have also been developed to induce CD8+ and CD4+ T-cell responses [44]. CD8+ T-cell responses obtained in mice with the long peptide seem to be stronger than with an MUC1 9 mer peptide. Peptidic MUC1 vaccines have also been combined with other reagents to improve their efficiency. For example, MUC1 glycopeptides have been covalently associated with T-helper peptide and TLR2 agonist in a multimodal vaccine [49]. This vaccine strategy was reported to induce a high level of MUC1-specific antibodies and MUC1-specific cytotoxic T lymphocytes, which showed superior capability to prevent tumors growth in mice than unglycosylated peptides.

5. MUC1-Based Immunotherapy: Clinical Studies

Some of these preclinical strategies are now being assessed for MUC1-based immunotherapy in clinical trials for different types of cancers. More than sixty clinical trials interested in MUC1 protein are currently in progress (http://www.clinicaltrials.gov/). The majority of these are developing vaccination strategies against MUC1 to treat cancer. This large number of trials highlights the clinical interest in MUC1 vaccination. Only three clinical studies have reached the phase IIIB/III stage. We have summarized in Table 2 the strategies which are currently being developed in these clinical trials. Some of these studies have shown a possible clinical effect of this vaccine in inducing an MUC1-specific T-cell response. Among them, some major strategies have emerged and reached phase III.

The BLP25 liposome vaccine (stimuvax or L-BLP25) is a liposomal vaccine containing a 25-amino-acid MUC1 peptide corresponding to the core peptide of MUC1 (STAP-PAHGVTSPADTPRAGSTAPP) and coupled with a palmitoyl lysine residue at the C terminus which increases incorporation of this lipopeptide into the liposome particle [74, 75]. This strategy is mostly being used in nonsmall-cell lung carcinoma (NSCLC) and is well tolerated [62, 76]. Even though no immunological response was observed, this vaccine seems to have enhanced patient survival for stage IIIB/IV NSCLC in a phase II clinical trial [63]. A phase III study is in progress to confirm this result [64].

Another major strategy is TG4010, from Transgene SA, which is a recombinant virus of the Modified Vaccinia Ankara (MVA), encoding MUC1 and IL-2 (MVA MUC1-IL2). Unlike the L-BLP25 which is being used on NSCLC only, TG4010 is being used against several types of cancer, including prostate cancer, renal cell carcinoma (RCC), and NSCLC [58–60]. In prostate cancer, evidence of biological activity of the vaccine has been observed, with improved prostate-specific antigen (PSA) level doubling time [59]. In RCC, preliminary results were encouraging showing that this vaccine is well tolerated and indicating some evidence of MUC1-specific CD4+ and CD8+ T-cell responses [60]. The
best clinical responses using TG4010 were observed for lung cancer. Indeed, TG4010 enhanced the effect of chemotherapy, with an increase in six-month, progression-free survival for patients who received chemotherapy in combination with the vaccine as compared with patients given chemotherapy only [61]. A phase IIB/III trial is currently being performed to evaluate the clinical advantage of combining chemotherapy plus TG4010 in NSCLC.

Encouraging results were also obtained in a pilot phase III clinical trial where early-stage breast cancer patients (stage II) were immunized with oxidized-mannan MUC1 [57]. No resurgence of the disease was observed in the sixteen patients who received the vaccine, whereas four patients among the fifteen who received a placebo relapsed.

Passive vaccination strategies are not the only way to exploit MUC1 T-cells response for immunotherapy. Adoptive immunotherapy (AIT) is another approach, which consists in the purification of patient PBMC (lymphocytes, dendritic cells in particular), followed by ex vivo stimulation of T cells and/or dendritic cell loaded with MUC1 peptides. These cells are then adoptively transferred back to the patients. Interest in this strategy is the ability of these T cells to kill patient tumor cells and the capacity of dendritic cells to enhance this T-cell response. The first clinical trial of MUC1 adoptive T-cells transfers showed no clinical response [77]. It was followed by combining the transfer of activated T lymphocytes with MUC1 peptides pulsed dendritic cells. This second clinical trial showed interesting clinical effects with one patient complete response [68]. At the same time, Lepisto and colleague reported that transfers of MUC1 peptide-pulsed dendritic cells can elicit specific MUC1 CD8+ and CD4+ response but did not induce benefit for patient survival [78]. All together, these studies suggest the need of combining T-cells and dendritic cells transfers to obtain optimal response in patients. In another study, Wright and colleague showed that tumor burden influences the quality of adoptively transferred MUC1 specific CTL. Indeed, CTL prepared from PBMC of treated breast cancer patients with no evidence of disease can generate CTL that kill cancer cells and produce type 1 cytokine. Inversely, CTL obtained from patients with macroscopic disease were infective [79]. More recently, it was shown that TH1 CD4+ lymphocytes transfers in combination with IFN-γ and IL-10 were effective to induce clinical response that enhances patient survival [69]. All these studies show the interest of adoptive transfers strategy for MUC1-based immunotherapy. However, the adoptive transfers approach needs ex vivo manipulation of cells which could be complex to perform compared to other passive vaccination strategies.

Behind these clinical trials which have reached phase III, many other MUC1 vaccines are being used to explore other ways of inducing specific MUC1 T-cell responses in breast, prostate, ovarian, pancreatic, and lung cancer, as summarized in Table 2. Furthermore, numerous studies have

| Author                  | Strategy                           | Clinical trial phase | Major observation                                      | Cancer type |
|-------------------------|------------------------------------|----------------------|--------------------------------------------------------|-------------|
| Apostolopoulset al. [57]| Oxidized Mannan-MUC1               | III                  | Breast cancer recurrence prevention                     | Breast      |
| Ramlau et al. [58]      | TG4010                             | II                   | TG4010 can be coupled with chemotherapy                | Lung        |
| Dreicer et al. [59]     | TG4010                             | II                   | Increased PSA doubling time                            | Prostate    |
| Oudard et al. [60]      | TG4010                             | II                   | MUC1 T cell responses                                  | RCC         |
| Quoix et al. [61]       | TG4010                             | IIIB                 | Improved survival                                      | Lung        |
| Ohyanagi et al. [62]    | BLP25                              | I/II                 | Well tolerated, low side effects                       | Lung        |
| Butts et al. [63]       | BLP25                              | II/B                 | Increased survival                                     | Lung        |
| WU et al. [64]          | BLP25                              | III inspire          | In progress/increased survival                        | Lung        |
| Butts et al. [65]       | BLP25                              | I/II                 | New formulation well tolerated                         | Lung        |
| Wright et al. [66]      | MUC1 TIL Transfers                 | I/II                 | Influence of the tumor burden on adoptive transfer of MUC1 specific T cells | Breast      |
| Lepisto et al. [67]     | Dendritic cells pulsed with MUC1   | I/II                 | Well tolerated, induction of T cell responses          | Pancreas    |
| Kondo et al. [68]       | Dendritic cells and CTL transfer   | I                    | Clinical response                                      | Pancreas    |
| Dobrzanski et al. [69]  | Adoptive transfer CD4 T cells plus IL-10 | I                  | Clinical response                                      | Ovarian     |
| Mohebtash et al. [70]   | PANVAC-VF                          | II                   | Clinical effects                                       | Breast/ovary |
| Ibrahim et al. [71]     | AS1402 + Letrosole                  | II                   | Use of Letrosole incompatible with AS1402 strategy     | Breast      |
| Pegram et al. [72]      | AS1402                             | I                    | Well tolerated, need phase II to evaluate efficacy     | Breast      |
| Rittig et al. [73]      | ARN muc1                           | I/II                 | Induction of CD4+ T cell responses                     | RCC         |

| Table 2: MUC1-based immunotherapy trials. |
described MUC1 as an oncogenic protein, advocating the development of pharmacological studies to counteract this protein. This is the case for toxins which target the cytoplasmic tail (see Figure 1) of MUC1 [80, 81] or molecules that downregulate MUC1 protein [82, 83]. Both pharmacological and immunotherapeutic strategies based on MUC1 to treat cancer should now be actively pursued.

**Abbreviations**

MPM: Malignant pleural mesothelioma  
MUC1: Mucin1  
TAA: Tumor associated antigen.

**Acknowledgments**

This work was financed by INSERM, La ligue régionale contre le Cancer (CSIRGO), the ARC (Association pour la recherche contre le cancer), the Nantes Hospital and the ARSMESO44 association.

**References**

[1] G. P. Dunn, L. J. Old, and R. D. Schreiber, “The three Es of cancer immunoediting,” *Annual Review of Immunology*, vol. 22, pp. 329–360, 2004.

[2] C. Traversari, P. van der Bruggen, I. F. Luescher et al., “A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E,” *Journal of Experimental Medicine*, vol. 176, no. 5, pp. 1453–1457, 1992.

[3] J. H. Kessler and C. J. M. Melief, “Identification of T-cell epitopes for cancer immunotherapy,” *Leukemia*, vol. 21, no. 9, pp. 1859–1874, 2007.

[4] S. Müller, K. Alving, J. Peter-Katalinic, N. Zachara, A. A. Gooley, and F. G. Hanisch, “High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast carcinoma,” *The Journal of Biological Chemistry*, vol. 274, no. 26, pp. 18165–18172, 1999.

[5] D. W. Kufe, “Functional targeting of the MUC1 oncogen in human cancers,” *Cancer Biology and Therapy*, vol. 8, no. 13, pp. 1197–1203, 2009.

[6] D. Kufe, “Oncogenic function of the MUC1 receptor subunit in gene regulation,” *Oncogene*, vol. 29, no. 42, pp. 5663–5666, 2010.

[7] S. J. Gendler, C. A. Lancaster, J. Taylor-Papadimitriou et al., “Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin,” *The Journal of Biological Chemistry*, vol. 265, no. 25, pp. 15286–15293, 1990.

[8] M. S. Lan, S. K. Batra, W. N. Qi, R. S. Metzgar, and M. A. Hollingsworth, “Cloning and sequencing of a human pancreatic tumor mucin cDNA,” *The Journal of Biological Chemistry*, vol. 265, no. 25, pp. 15294–15299, 1990.

[9] J. Burchell, S. Gendler, J. Taylor-Papadimitriou et al., “Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin,” *Cancer Research*, vol. 47, no. 20, pp. 5476–5482, 1987.

[10] A. Girling, J. Bartkova, J. Burchell, S. Gendler, C. Gillett, and J. Taylor-Papadimitriou, “A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas,” *International Journal of Cancer*, vol. 43, no. 6, pp. 1072–1076, 1989.

[11] H. Takeuchi, K. Kato, K. Denda-Nagai, F. G. Hanisch, H. Clausen, and T. Irimura, “The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialylalpha-3galactosylbeta-1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat,” *Journal of Immunological Methods*, vol. 270, no. 2, pp. 199–209, 2002.

[12] K. O. Lloyd, J. Burchell, V. Kudryashov, B. W. T. Yin, and J. Taylor-Papadimitriou, “Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines: demonstration of simpler and fewer glycan chains in tumor cells,” *The Journal of Biological Chemistry*, vol. 271, no. 52, pp. 33325–33334, 1996.

[13] G. F. Springer, “T and Th, general carcinoma autoantigens,” *Science*, vol. 224, no. 4654, pp. 1198–1206, 1984.

[14] D. L. Barnd, M. S. Lan, R. S. Metzgar, and O. J. Finn, “Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 86, no. 18, pp. 7159–7163, 1989.

[15] C. G. Ioannides, B. Fisk, K. R. Jerome, T. Irimura, J. T. Wharton, and O. J. Finn, “Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides,” *Journal of Immunology*, vol. 151, no. 7, pp. 3693–3703, 1993.

[16] T. Takahashi, Y. Makiguchi, Y. Hinoda et al., “Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient,” *Journal of Immunology*, vol. 153, no. 5, pp. 2102–2109, 1994.

[17] H. Noto, T. Takahashi, Y. Makiguchi, T. Hayashi, Y. Hinoda, and K. Imai, “Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin,” *International Immunology*, vol. 9, no. 5, pp. 791–798, 1997.

[18] K. R. Jerome, D. L. Barnd, K. M. Bendt et al., “Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells,” *Cancer Research*, vol. 51, no. 11, pp. 2908–2916, 1991.

[19] Y. Hinoda, T. Takahashi, T. Hayashi et al., “Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells,” *Journal of Gastroenterology*, vol. 33, no. 2, pp. 164–171, 1998.

[20] N. Domenech, R. A. Henderson, and O. J. Finn, “Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin,” *Journal of Immunology*, vol. 155, no. 10, pp. 4766–4774, 1995.

[21] V. Apostolopoulos, V. Karanikas, J. S. Haurum, and I. F. C. McKenzie, “Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen,” *Journal of Immunology*, vol. 159, no. 11, pp. 5211–5218, 1997.

[22] P. Brossart, K. S. Heinrich, G. Stuhler et al., “Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies,” *Blood*, vol. 93, no. 12, pp. 4309–4317, 1999.

[23] P. Brossart, A. Schneider, P. Dill et al., “The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes,” *Cancer Research*, vol. 61, no. 18, pp. 6846–6850, 2001.
D. Roulois, V. Vignard, F. Gueugnon et al., “Recognition of pleural mesothelioma by mucin-1(950–958)/human leukocyte antigen A’0201-specific CD8+ T-cells,” European Respiratory Journal, vol. 38, no. 5, pp. 1117–1126, 2011.

T. Ninkovic, L. Kinarsky, K. Engelmann et al., “Identification of O-glycosylated decapetides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes,” Molecular Immunology, vol. 47, no. 1, pp. 131–140, 2009.

E. M. Hiltbold, P. Ciborowski, and O. J. Finn, “Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T-cells,” Cancer Research, vol. 58, no. 22, pp. 5066–5070, 1998.

E. M. Hiltbold, M. D. Alter, P. Ciborowski, and O. J. Finn, “Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells,” Cellular Immunology, vol. 194, no. 2, pp. 143–149, 1999.

A. M. Vlad, S. Muller, M. Cudic et al., “Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells,” Journal of Experimental Medicine, vol. 196, no. 11, pp. 1435–1446, 2002.

C. Napoletano, A. Rughetti, M. P. Agervig Tarp et al., “Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells,” Cancer Research, vol. 67, no. 17, pp. 8358–8367, 2007.

E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn, “The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells,” Journal of Immunology, vol. 165, no. 7, pp. 3730–3741, 2000.

T. Ninkovic and F. G. Hanisch, “O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes,” Journal of Immunology, vol. 179, no. 4, pp. 2380–2388, 2007.

N. Peat, S. J. Gendler, E. N. Lalani, T. Duhig, and J. Taylor-Papadimitriou, “Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice,” Cancer Research, vol. 52, no. 7, pp. 1954–1960, 1992.

M. M. Soares, V. Mehta, and O. J. Finn, “Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection,” Journal of Immunology, vol. 166, no. 11, pp. 6555–6563, 2001.

K. G. Kohlgraf, A. J. Gawron, M. Higashi et al., “Tumor-specific immunity in MUC1Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1),” Cancer Immunology. Immunotherapy, vol. 53, no. 12, pp. 1068–1084, 2004.

G. J. Rowse, R. M. Tempero, M. L. VanLith, M. A. Hollingsworth, and S. J. Gendler, “Tolerance and immunity to MUC1 in a human MUC1 transgenic marine model,” Cancer Research, vol. 58, no. 2, pp. 315–321, 1998.

R. M. Tempero, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth, “Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice,” International Journal of Cancer, vol. 80, no. 4, pp. 595–599, 1999.

R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth, “CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice,” Journal of Immunology, vol. 161, no. 10, pp. 5500–5506, 1998.

S. K. Tang, K. C. Sheng, D. Pouliot et al., “Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses,” Vaccine, vol. 26, no. 31, pp. 3827–3834, 2008.

A. M. Farkas and O. J. Finn, “Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation,” Seminars in Immunology, vol. 22, no. 3, pp. 125–131, 2010.

T. Deguchi, M. Tanemura, E. Miyoshi et al., “Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express α-Gal epitopes: a novel approach to immunotherapy in pancreatic cancer,” Cancer Research, vol. 70, no. 13, pp. 5239–5269, 2010.

R. Kovjazin, I. Volovitz, Y. Kundel et al., “ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors,” Vaccine, vol. 29, no. 29-30, pp. 4676–4686, 2011.

D. H. Choi, J. K. Woo, Y. Choi, H. S. Seo, and C. W. Kim, “A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene,” Molecular Medicine Reports, vol. 4, no. 5, pp. 885–890, 2011.

J. Chen, H. Y. Li, D. Wang, J. J. Zhao, and X. Z. Guo, “Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro,” Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1509–1518, 2011.

S. E. Wright, I. S. Quinlin, K. A. Rewers-Felkins, K. E. Domrowski, and C. A. Phillips, “Retention of immunogenicity produced by mucin1 peptides with glycosylation site substitutions,” Immunopharmacology and Immunotoxicology, vol. 32, no. 4, pp. 647–655, 2010.

S. Kobukai, G. J. Kremer, J. G. Cobb et al., “Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 peptide antigen,” Translational Oncology, vol. 4, no. 1, pp. 1–8, 2011.

V. Lakshminarayanan, P. Thompson, M. A. Wolfert et al., “Immun recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 1, pp. 261–266, 2012.

D. Sugiuara, S. Aida, K. Denda-nagai et al., “Differential effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and
metastases," Cancer Science, vol. 99, no. 12, pp. 2477–2484, 2008.

[51] Y. Choi, Y. H. Jeon, J. Y. Jang, J. K. Chung, and C. W. Kim, "Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination," Molecular Therapy, vol. 19, no. 5, pp. 979–989, 2011.

[52] Y. H. Jeon, Y. Choi, H. J. Kim et al., "In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination," Molecular Imaging, vol. 6, no. 5, pp. 297–303, 2007.

[53] C. Trumpfeller, M. P. Longhi, M. Caskey et al., "Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity," Journal of Internal Medicine, vol. 271, no. 2, pp. 183–192, 2012.

[54] Y. Rong, D. Jin, W. Wu et al., "Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine," BMC Cancer, vol. 9, article 191, 2009.

[55] D. Massé, F. Ebstein, G. Bougras, J. Harb, K. Meflah, and M. Grégoire, "Increased expression of inducible HSF70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy," International Journal of Cancer, vol. 111, no. 4, pp. 575–583, 2004.

[56] J. Pinkhasov, M. L. Alvarez, M. M. Rigano et al., "Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1 tg mice," Plant Biotechnology Journal, vol. 9, no. 9, pp. 991–1001, 2011.

[57] V. Apostolopoulos, G. A. Pietersz, A. Tsibanis et al., "Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]," Breast Cancer Research, vol. 8, no. 3, article R27, 2006.

[58] R. Ramlau, E. Quoix, J. Rolski et al., "A phase II study of Tg4010 (Mva-Muc1-II2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer," Journal of Thoracic Oncology, vol. 3, no. 7, pp. 735–744, 2008.

[59] R. Dreicer, W. M. Stdoller, F. R. Ahmann et al., "MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure," Investigational New Drugs, vol. 27, no. 4, pp. 379–386, 2009.

[60] S. Oudard, O. Rixe, B. Beuselinck et al., "A phase II study of the cancer vaccine Tg4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings," Cancer Immunology, Immunotherapy, vol. 60, no. 2, pp. 261–271, 2011.

[61] E. Quoix, R. Ramlau, V. Westeel et al., "Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial," The Lancet Oncology, vol. 12, no. 12, pp. 1125–1133, 2011.

[62] F. Ohyanagi, T. Horai, I. Sekine et al., "Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III nsclc after primary chemoradiotherapy: preliminary results from a phase I/II study," Japanese Journal of Clinical Oncology, vol. 41, no. 5, Article ID hyr021, pp. 718–722, 2011.

[63] C. Buts, A. Maksymiuk, G. Goss et al., "Updated survival analysis in patients with stage IIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial," Journal of Cancer Research and Clinical Oncology, vol. 137, no. 9, pp. 1337–1342, 2011.

[64] Y. L. Wu, K. Park, R. A. Soo et al., "INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer," BMC Cancer, vol. 11, article 430, 2011.

[65] C. Buts, R. N. Murray, C. Smith et al., "A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with resectable stage III non-small-cell lung cancer," Clinical Lung Cancer, vol. 11, no. 6, pp. 391–395, 2010.

[66] S. E. Wright, K. A. Rewers-Felkins, I. S. Quinlin et al., "Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients—a phase III study tumor burden influences CTL development," Immunological Investigations, vol. 38, no. 8, pp. 820–838, 2009.

[67] A. J. Lepisto, A. J. Moser, H. Zeh et al., "A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors," Cancer Therapy, vol. 6, no. B, pp. 955–964, 2008.
[79] S. E. Wright, K. A. Rewers-Felkins, I. S. Quinlin et al., “Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients—a phase I/II study,” Immunological Investigations, vol. 38, no. 8, pp. 820–838, 2009.

[80] D. Raina, R. Ahmad, H. Rajabi et al., “Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells,” International Journal of Oncology, vol. 40, no. 5, pp. 1643–1649, 2012.

[81] D. Raina, M. Kosugi, R. Ahmad et al., “Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells,” Molecular Cancer Therapeutics, vol. 10, no. 5, pp. 806–816, 2011.

[82] M. J. Brayman, N. Dharmaraj, E. Lagow, and D. D. Carson, “MUC1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-y,” Molecular Endocrinology, vol. 21, no. 11, pp. 2725–2737, 2007.

[83] D. Roulois, C. Blanquart, C. Panterne et al., “Downregulation of MUC1 expression and its recognition by CD8+ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi,” European Journal of Immunology, vol. 42, no. 3, pp. 783–789, 2012.